The trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with malignant ascites: Immunomonitoring results of a pivotal phase II/III study (pooled population)

被引：0
|
作者：
Jaeger, M.
Schoberth, A.
Hennig, M.
Burges, A.
Heiss, M.
Wimberger, P.
Schmalfeldt, B.
Lindhofer, H.
机构：
[1] TRION Res GmbH, Martinsried, Germany
[2] Fresenius Biotech GmbH, Munich, Germany
[3] Univ Munich, Dept Gynecol & Obstet, Munich, Germany
[4] Univ Cologne Witten Herdecke, Dept Surg, Cologne, Germany
[5] AGO, Essen, Germany
[6] AGO, Munich, Germany
[7] TRION Pharma GmbH, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2521
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo
    Kirsten Dettmar
    Isabell Seitz-Merwald
    Carsten Lindemann
    Petra Schroeder
    Diane Seimetz
    Judith Atz
    Clinical and Translational Oncology, 2012, 14 : 376 - 381
  • [32] An evaluation of anti-EpCAM x anti-CD3 bispecific antibody using patients derived cancer organoids.
    Tsumura, Ryo
    Komatsu, Teruo
    Koga, Yoshikatsu
    Yasunaga, Masahiro
    CANCER SCIENCE, 2025, 116 : 300 - 300
  • [33] Peritoneal carcinomatosis immunotherapy with the trifunctional anti-EpCAM x anti-CD3 antibody catumaxomab in patients with colon, gastric, or pancreatic cancer: Long-term results after a 2-year follow-up
    Stroehlein, M.
    Lordick, F.
    Ruettinger, D.
    Schemanski, O.
    Jaeger, M.
    Lindhofer, H.
    Hennig, M.
    Lahr, A.
    Heiss, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinoma prior to gastrectomy
    Knoedler, M.
    Koerfer, J.
    Kunzmann, V.
    Trojan, J.
    Daum, S.
    Schenk, M.
    Kullmann, F.
    Schroll, S.
    Behringer, D.
    Stahl, M.
    Al-Batran, S. -E.
    Hacker, U.
    Lordick, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 158 - 158
  • [35] Intraperitoneal administration of the trifunctional antibody catumaxomab for treatment of malignant ascites due to ovarian carcinoma: Results of a phase II/III study
    Parsons, S.
    Kutarska, E.
    Koralewski, P.
    Gore, M.
    Wimberger, R.
    Burges, A.
    Sroehlein, M. A.
    Friccius-Quecke, H.
    Jaeger, M.
    Heiss, M. M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 311 - 311
  • [36] Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.
    Qi, Changsong
    Wu, Shikai
    Kim, In-Ho
    Cai, Shirong
    Wang, Jufeng
    Kim, Seung Tae
    Wang, Jaw-Yuan
    Bai, Li-Yuan
    Lin, Cheng-Yao
    Liang, Zhezhao
    Wei, Jian Xin
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16102 - E16102
  • [37] Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
    Ott, Marion G.
    Marme, Frederik
    Moldenhauer, Gerhard
    Lindhofer, Horst
    Hennig, Michael
    Spannagl, Rolf
    Essing, Mirko M.
    Linke, Rolf
    Seimetz, Diane
    INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (09) : 2195 - 2203
  • [38] Randomized, multicenter, two-dose level, open-label, phase IIA study with theintraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EPCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients
    Burges, A.
    Pfisterer, J.
    Wimberger, P.
    Kurzeder, C.
    du Bois, A.
    Sehouli, J.
    Loibl, S.
    Burchardi, N.
    Vergote, I.
    Wagner, U.
    ONKOLOGIE, 2008, 31 : 102 - 102
  • [39] Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients
    Belau, A.
    Pfisterer, J.
    Wimberger, P.
    Kurzeder, C.
    Du Bois, A.
    Sehouli, J.
    Loibl, S.
    Burchardi, N.
    Vergote, I.
    Wagner, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients
    Loibl, S.
    Pfisterer, J.
    Wimberger, P.
    Kurzeder, C.
    Du Bois, A.
    Sehouli, J.
    Belau, A.
    Burchardi, N.
    Vergote, I.
    Wagner, U.
    EJC SUPPLEMENTS, 2007, 5 (04): : 312 - 312
12345